← Leaderboards
Salimah H. Meghani
University Of Pennsylvania
$5,248,349
Attributed
$8,387,001
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,387,001 · 5
By mechanism
R01$5,515,776 · 2
U01$1,905,214 · 1
RC1$845,947 · 1
K01$120,064 · 1
Top collaborators
- Rebecca Ashare10 shared
- Brooke Worster6 shared
- Shannon Madore Nugent2 shared
- Shannon Nugent1 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- David T Grande$2,383,148
- Brooke Worster$921,452
- Anna Rose Childress$14,753,643
- Kyle Matthew Kampman$31,481,891
- Paul F Crits-Christoph$12,594,443
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainReportingCancer TherapyMalignant NeoplasmsSeveritiesCancer PainSchedulePatient Outcomes AssessmentsCancer ScienceQuality Of LifeCancer PatientDesignPain ManagementAfrican AmericanSymptomsOncologyRaceSide EffectAreaOpioid UseOpioid MisuseOpioid TherapyCancer Pain ManagementAmerican
Grant awards (19)
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$662,839
R01 · FY2025 · CA · contact PI
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study$629,354
U01 · FY2025 · CA
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$70,531
R01 · FY2025 · CA · contact PI
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$620,322
R01 · FY2024 · CA · contact PI
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study$599,442
U01 · FY2024 · CA
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$68,605
R01 · FY2024 · CA · contact PI
Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study$676,418
U01 · FY2023 · CA
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$642,629
R01 · FY2023 · CA · contact PI
The Role of Opioid Adherence Profiles in Cancer Pain Self-Management and Outcomes$509,322
R01 · FY2023 · NR · contact PI
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$51,212
R01 · FY2023 · CA · contact PI
Cannabis use and outcomes in ambulatory patients with cancer: A 12-month cohort study$699,429
R01 · FY2022 · CA · contact PI
The Role of Opioid Adherence Profiles in Cancer Pain Self-Management and Outcomes$529,793
R01 · FY2022 · NR · contact PI
The Role of Opioid Adherence Profiles in Cancer Pain Self-Management and Outcomes$541,476
R01 · FY2021 · NR · contact PI
The Role of Opioid Adherence Profiles in Cancer Pain Self-Management and Outcomes$554,658
R01 · FY2020 · NR · contact PI
The Role of Opioid Adherence Profiles in Cancer Pain Self-Management and Outcomes$564,960
R01 · FY2019 · NR · contact PI
A Novel Approach to Elucidate Mechanisms for Disparity in Cancer Pain Outcomes$397,330
RC1 · FY2010 · NR · contact PI
A Novel Approach to Elucidate Mechanisms for Disparity in Cancer Pain Outcomes$448,617
RC1 · FY2009 · NR · contact PI
Disparities in Analgesic Preference for Cancer Pain: A Conjoint Analysis Study$28,965
K01 · FY2009 · NR · contact PI
Disparities in Analgesic Preference for Cancer Pain: A Conjoint Analysis Study$91,099
K01 · FY2008 · NR · contact PI